The research presented in this paper was conducted by the Oncology Real World Solutions team at IQVIA Canada and was sponsored by AstraZeneca Canada. AstraZeneca and IQVIA partnered through project CORE (Championing Oncology Relevant Endpoints) which aims to expand the acceptability of oncology relevant endpoints by regulatory authorities, HTA agencies and payers in Canada within the solid tumour space.
Full spectrum of expertise in Market Access, Health Economics & Outcomes Research, and Real World Evidence (RWE)